Streetbeat News

Revenues

SNV

Synovus Financial Corp (NYSE:SNV) has been the subject of diverse analyst opinions over the past three months, with 8 analysts offering ratings that range from bullish to indifferent. The average 12-month price target for SNV has increased by 11.77% to $37.88, with a high estimate of $46.00 and a low of $31.00. Recent analyst actions include both raised and lowered price targets and ratings. Synovus provides a range of banking services and has four main segments, with Wholesale Banking being the largest. The company's market capitalization is below the industry average, and it has experienced a revenue decline of -11.28% as of September 30, 2023. Additionally, Synovus has a net margin of 16.93%, an ROE of 2.12%, an ROA of 0.15%, and a debt-to-equity ratio of 0.68, all of which are below industry standards.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 1:00 pm

BKNG

RYAAY

Ryanair Holdings PLC (NASDAQ: RYAAY) stock is trading lower after the company reported its December data, which included a 9% increase in guest count but a 1 percentage point decrease in load factor year-over-year. The company also announced that its flights were removed from several OTA websites, including Booking Holdings Inc. (NASDAQ: BKNG) platforms, due to regulatory pressures. This removal is expected to reduce short-term load factors by 1-2% in December and January and weaken yields. Ryanair plans to lower fares to mitigate the impact and does not anticipate a material effect on its FY24 traffic or profit after tax (PAT) guidance. RYAAY shares dropped 3.16% in premarket trading.

Portfolio Pulse from Lekha Gupta

January 03, 2024 | 12:39 pm

AGFY

Agrify Corporation reported a significant decline in revenue for Q3 FY23, posting $3.1 million compared to $7 million in Q3 FY22. The company also reported a loss per share (EPS) of $(1.27).

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 12:37 pm

SLS

SELLAS Life Sciences Group, Inc. has provided updates on its corporate activities and outlined key milestones for 2024. These include interim analysis of the Phase 3 REGAL study of Galinpepimut-S in Acute Myeloid Leukemia (AML) patients expected in Q1 2024, topline data from a Phase 2a study of SLS009 in relapsed/refractory AML patients also expected in Q1 2024, and topline data from a Phase 1b/2 study in relapsed/refractory Peripheral T-cell Lymphoma patients expected in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 12:35 pm

ABVC

ABVC BioPharma and its subsidiary have received a $460 million milestone payment from AiBtl BioPharma as part of global licensing fees. This significant financial inflow could impact ABVC's short-term financial position and potentially its stock price.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 12:26 pm

AEXAF

EADSY

Atos SE has received non-binding interest in its Big Data & Security (BDS) business, with Airbus SE making an indicative offer of €1.5 billion-€1.8 billion for the entire unit. The potential acquisition would enhance Airbus's defense and security capabilities with advanced cybersecurity, computing, and AI. Atos is entering a due diligence phase with Airbus and continues exclusive negotiations with EPEI for the sale of Tech Foundations. Atos may sell additional assets to reduce debt and realign its business.

Portfolio Pulse from Shivani Kumaresan

January 03, 2024 | 12:24 pm

PRU

Prudential Financial (NYSE:PRU) received mixed analyst ratings over the past three months, with a total of 1 bullish, 1 somewhat bullish, and 3 indifferent ratings. The average 12-month price target for PRU has been raised to $115.4, with a high estimate of $132.00 and a low estimate of $103.00. Analysts from JP Morgan and Morgan Stanley have adjusted their price targets and ratings, reflecting their latest views on the company's performance. Prudential Financial's financials show a significant revenue decline of -58.79% as of September 30, 2023, a net margin of -9.71%, an ROE of -2.98%, an ROA of -0.12%, and a high debt-to-equity ratio of 0.79, indicating potential challenges ahead.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 12:00 pm

ROK

Rockwell Automation (NYSE:ROK) has received mixed ratings from 4 financial analysts in the last three months, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for ROK is now $333.00, up 15.83% from the previous target of $287.50. Analysts from UBS, Wells Fargo, Mizuho, and Stephens & Co. have provided updated ratings and price targets, reflecting their views on the company's market performance and financial health. Rockwell Automation, known for its automation solutions, has shown a revenue growth of 20.53% as of September 30, 2023, but lags behind industry peers. The company has a strong net margin of 7.73% and ROE of 5.74%, but carries a higher debt-to-equity ratio of 0.94.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 12:00 pm

LNC

Five analysts have recently updated their ratings on Lincoln National (NYSE:LNC), with a shift towards a more bearish stance over the past three months. The average 12-month price target is now $27.00, down from $28.00, with a high estimate of $30.00 and a low of $25.00. Analysts from JP Morgan, Evercore ISI Group, Piper Sandler, Morgan Stanley, and Wells Fargo have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Lincoln National's financials show a negative revenue trend with a -11.9% decline in revenue growth, but strong profitability with a net margin of 19.37% and high ROE of 23.25%. However, the company faces debt management challenges with a debt-to-equity ratio of 2.67.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 12:00 pm

TALO

Talos Energy has commenced production at its Lime Rock and Venice discoveries in the Gulf of Mexico. This development is expected to contribute positively to the company's output and financial performance.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 12:00 pm